KDR and renal cell adenocarcinoma: A Phase III trial in untreated advanced RCC (KEYNOTE‐426) revealed pembrolizumab (anti‐PD‐1) plus axitinib (anti‐VEGFR) with PFS of 15.1 months and ORR 59.3% was more effective than sunitinib with PFS of 11.1 months and ORR 35.7%.